Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -90 million and -60 million yuan, indicating continued losses compared to the previous year [4]. - The estimated net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -49.98 million and -19.98 million yuan [5]. - In the previous year, the total profit was -5.4686 million yuan, with a net profit attributable to shareholders of the parent company at -14.5872 million yuan [6]. Goodwill Impairment - The company plans to recognize goodwill impairment for the Wuhan Huake Reproductive Obstetrics Hospital asset group, estimated between 80 million and 90 million yuan, which is the main reason for the projected negative net profit [7]. Audit and Investment Risks - The preliminary financial data has not been audited by an accounting firm and is subject to change [8]. - The company has communicated with the annual audit accountant and appraisers regarding the performance forecast [8]. - Investors are advised to pay attention to investment risks as the final audited financial data will be disclosed in the 2025 annual report [9].

Core Viewpoint - Han Commercial Group has issued an annual performance forecast indicating a projected net loss attributable to shareholders of the listed company for 2025, ranging from -90 million to -60 million yuan [1] Financial Performance - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -49.98 million and -19.98 million yuan for 2025 [1] - The company is adhering to the "Enterprise Accounting Standards" and related accounting policies, conducting year-end impairment tests on relevant assets [1] Impairment and Valuation - The company plans to recognize goodwill impairment for the asset group of Wuhan Huake Reproductive Obstetrics Hospital, with an estimated impairment amount between 80 million and 90 million yuan [1] - This non-cash impairment is identified as the primary reason for the projected negative net profit in 2025 [1] - The final amount of goodwill impairment will be determined by the evaluation and audit conducted by the company's appointed assessment and audit institutions [1]

Group 1: Market Overview - The market experienced significant activity with over 3,900 stocks rising, and the North Stock 50 Index surged over 3% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 3.09 trillion, an increase of 393.5 billion compared to the previous trading day [1] - Key sectors leading the market included photovoltaic, commercial aerospace, gold, and AI applications [1] Group 2: Company Highlights - Fenglong Co., Ltd. (002931) achieved an 18-day consecutive limit-up, with a price increase of 405.74% from December 25, 2025, to January 23, 2026, and is now under trading suspension for risk assessment [2] - Xian Dao Intelligent (300450) projected a net profit of 1.5 billion to 1.8 billion for 2025, representing a year-on-year growth of 424.29% to 529.15%, driven by a recovery in the global power battery market and strong demand in the energy storage sector [3] - The company is enhancing its cash flow management and improving its operational resilience through accelerated equipment acceptance and payment collection [3] Group 3: New Stock Offering - A new stock, Beixin Life, is available for subscription on January 26, 2026, with an issue price of 17.52, listed on the Shanghai Stock Exchange, and belongs to the medical consumables sector [5] Group 4: External Market Influence - The Nasdaq Composite Index rose by 0.28%, while the Dow Jones Industrial Average fell by 0.58%, indicating mixed performance in the U.S. stock market [7] - The precious metals sector led the gains, with Pan American Silver rising over 4% [7]

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

Group 1 - The core viewpoint of the news is that the A-share market is seeing a strong performance in innovative drug concept stocks, driven by a policy encouraging the sale of innovative drugs and reference preparations in retail pharmacies [1] Group 2 - Guangshentang (300436) experienced a 20% increase, with a total market value of 15.3 billion and a year-to-date increase of 8% [2] - Zhongsan Co. (301093) rose by 12%, with a market capitalization of 13.8 billion and a year-to-date increase of 63.89% [2] - Hanshang Group (600774) saw a 10% increase, with a market value of 3.408 billion and a year-to-date increase of 26.37% [2] - Hite Bio (300683) increased by 7.92%, with a market capitalization of 4.371 billion and a year-to-date increase of 20.41% [2] - Bibete (688759) rose by 6.64%, with a market value of 24.9 billion and a year-to-date increase of 90.09% [2] - Shutaishen (300204) increased by 5.78%, with a market capitalization of 13.6 billion and a year-to-date increase of 4.58% [2] - Chengdu Xian Dao (688222) rose by 5.42%, with a market value of 13.8 billion and a year-to-date increase of 46.78% [2] - Haiwang Bio (000078) increased by 5.23%, with a market capitalization of 10.1 billion and a year-to-date increase of 10.40% [2] - Jiuzhoutong (600998) rose by 4.71%, with a market value of 28 billion and a year-to-date increase of 8.59% [2] - Hongbo Pharmaceutical (301230) increased by 4.60%, with a market capitalization of 6.76 billion and a year-to-date increase of 62.48% [2] - Huana Pharmaceutical (688799) rose by 4.09%, with a market value of 6.882 billion and a year-to-date increase of 9.87% [2]

Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

Core Viewpoint - The stock of Han Commercial Group Co., Ltd. has experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days [2][4]. Group 1: Stock Trading Abnormality - The company's stock price increased by more than 20% cumulatively over three trading days (January 16, 2026, January 19, 2026, and January 20, 2026) [2][4]. - The trading activity is classified as an abnormal fluctuation according to the Shanghai Stock Exchange trading rules [2][4]. Group 2: Company Operations and Major Events - The company has confirmed that there have been no significant changes in its daily operations, market environment, or industry policies [5]. - There are no undisclosed major events affecting the company, aside from previously announced significant asset restructuring [6]. - The company has not identified any media reports or market rumors that could impact its stock price [7]. Group 3: Shareholder Activity - During the period of abnormal stock trading, the controlling shareholders and actual controllers did not engage in buying or selling the company's stock [3][8]. - The previously announced major asset restructuring has not made substantial progress or changes [9]. Group 4: Board Statement - The board of directors confirms that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange listing rules [12].

证券代码：600774 股票简称：汉商集团 编号：2026-001 汉商集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 汉商集团股份有限公司（以下简称"公司"）股票交易连续 3 个交易日内（2026 年 1 月 16 日、2026 年 1 月 19 日、2026 年 1 月 20 日）收盘价格涨幅偏离值累计超过 20%。 根据《上海证券交易所交易规则》的相关规定，公司股票交易属于异常波动情况。 截至本公告披露日，公司、控股股东及实际控制人除前期发布的重大资产重组事 项外，不存在其他应披露而未披露的重大事项，包括但不限于重大资产重组、股份发行、 收购、债务重组、业务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重 大业务合作、引进战略投资者等重大事项。 在公司本次股票交易异常波动期间，控股股东及实际控制人不存在买卖公司股票 的情况。 一、股票交易异常波动的具体情况 股票交易连续3个交易日内（2026年1月16日、2026年1月19日、2026年1月 20日）收盘价 ...

卓尔控股有限公司 关于股票交易异常波动有关情况的回函 汉商集团股份有限公司： 2、在贵公司本次股票交易异常波动期间，本公司及一致行动人不存在买卖 汉商集团股票的情况。 3、在贵公司本次股票交易异常波动期间，本公司及一致行动人未出现其他 可能对上市公司股价产生较大影响的重大事件。 4、在贵公司本次股票交易异常波动期间，本公司及一致行动人不存在其他 应披露而未披露的事项。 特此回函。 股有限公 2026年1月20日 贵公司《关于重大事项的询证函》已收悉。本公司作为贵公司控股股东， 经核查，现将有关事项回函如下： 1、截至本函回复之日，除前期已披露的重大资产重组事项外，本公司及一 致行动人未筹划涉及上市公司的其他重大资产重组、股份发行、收购、债务重 组、业务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大 业务合作、引进战略投资者等重大事项。 ...

Group 1 - The company announced that its stock price experienced an abnormal fluctuation, with a cumulative deviation of over 20% during three consecutive trading days on January 16, 19, and 20, 2026 [1] - The company conducted a self-examination and found no significant changes in daily operations or major events during the period of abnormal fluctuation [1] - The controlling shareholder, Zhuoer Holdings, and its concerted actor Yan Zhi hold a total of 92,594,710 shares, accounting for 31.38% of the total share capital, with 30,540,000 shares pledged, representing 32.98% of their total holdings and 10.35% of the total share capital, with no current risk of forced liquidation [1]